Abstract: This invention provides a method of treating a tumor in a warm-blooded animal, including humans, by administering, in combination, an anti-tumor effective amount of tegafur, uracil, folinic acid or pharmaceutically acceptable salt thereof and cyclophosphamide.
Type:
Grant
Filed:
April 19, 2002
Date of Patent:
September 16, 2003
Assignee:
Bristol-Myers Squibb Company
Inventors:
Eric P. Winer, Craig A. Bunnell, Jody Ressler-Tatro, Terry S. Dugan
Abstract: Disclosed are quinoline and benzazepine derivatives that inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogenic protein Ras. Thus, the compounds are useful as anti-cancer agents. The compounds are also useful in the treatment of diseases other than cancer.
Type:
Grant
Filed:
May 5, 2000
Date of Patent:
August 5, 2003
Assignee:
Bristol-Myers Squibb Company
Inventors:
Rajeev S. Bhide, Charles Z. Ding, John T. Hunt, Soong-Hoon Kim, Katerina Leftheris
Abstract: The present invention provides a synergistic method for the treatment of cancer which comprises administering to a mammalian specie in need thereof a synergistically, therapeutically effective amount of: (1) at least agent selected from the group consisting of cytotoxic agents and cytostatic agents, and (2) a compound of formula I
or a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition for the synergistic treatment of cancer which comprises at least one agent selected from the group consisting of antiproliferative cytotoxic agents and antiproliferative cytostatic agents, a compound of formula I, and a pharmaceutically acceptable carrier.
Abstract: Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by compounds of the formulas
their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof.
Type:
Grant
Filed:
April 21, 2000
Date of Patent:
October 1, 2002
Assignee:
Bristol-Myers Squibb Company
Inventors:
Charles Z. Ding, John T. Hunt, Katerina Leftheris, Rajeev S. Bhide
Abstract: Inhibition of farnesyl transferase, which is an enzyme involved in ras ocogene expression, is effected by compounds of the formulas
their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof inhibit farnesyl protein transferase which is an enzyme involved in ras oncogene expression.
Type:
Grant
Filed:
August 13, 1999
Date of Patent:
September 24, 2002
Assignee:
Bristol-Myers Squibb Company
Inventors:
Charles Z. Ding, Soong-Hoon Kim, John T. Hunt, Toomas Mitt, Rajeev Bhide, Katerina Leftheris